Compare
Quince Therapeutics, Inc. vs LeonaBio, Inc. vs Surrozen, Inc. vs Aligos Therapeutics, Inc.
| Latest fiscal year | Quince Therapeutics, Inc. IRLA | LeonaBio, Inc. LONA | Surrozen, Inc. SRZN | Aligos Therapeutics, Inc. ALGS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $3.48M | $2.19M |
| Revenue growth (YoY) | n/a | n/a | -67.4% | -39.5% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | n/m |
| Net margin | n/a | n/a | n/m | n/m |
| Net income | -$83.98M | -$105.61M | -$242.03M | -$24.19M |
| EPS (Diluted) | -$1.68 | -$24.70 | -$32.37 | -$2.45 |
| Operating cash flow | -$41.42M | -$45.73M | -$30.24M | -$82.50M |
| Free cash flow | -$41.78M | n/a | -$30.37M | n/a |
| Cash & equivalents | $5.81M | $69.28M | $89.25M | $18.30M |
| Total assets | $93.52M | $92.15M | $98.73M | $88.53M |
| Total liabilities | $129.24M | $64.36M | $286.49M | $34.99M |
| Shareholders' equity | -$35.71M | $27.79M | -$187.76M | $53.55M |
| Return on year-end equity | n/a | -380.0% | n/a | -45.2% |
| Shares outstanding | 55.73M | 9.34M | 9.78M | 6.18M |
Revenue, most recent five fiscal years
| Fiscal year | Quince Therapeutics, Inc. | LeonaBio, Inc. | Surrozen, Inc. | Aligos Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $3.48M Ended 2025-12-31 | $2.19M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $10.65M Ended 2024-12-31 | $3.61M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | $6.19M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $12.50M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $0 Ended 2021-12-31 | $0 Ended 2021-12-31 |